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Abstract
In a recent cluster analysis, it has been shown that patients with peripheral neuropathic pain can be grouped into 3 sensory
phenotypes based on quantitative sensory testing profiles, which are mainly characterized by either sensory loss, intact sensory
function and mild thermal hyperalgesia and/or allodynia, or loss of thermal detection and mild mechanical hyperalgesia and/or
allodynia. Here, we present an algorithm for allocation of individual patients to these subgroups. The algorithm is
nondeterministic—ie, a patient can be sorted to more than one phenotype—and can separate patients with neuropathic pain
from healthy subjects (sensitivity: 78%, specificity: 94%). We evaluated the frequency of each phenotype in a population of patients
with painful diabetic polyneuropathy (n 5 151), painful peripheral nerve injury (n 5 335), and postherpetic neuralgia (n 5 97) and
propose sample sizes of study populations that need to be screened to reach a subpopulation large enough to conduct
a phenotype-stratified study. The most common phenotype in diabetic polyneuropathy was sensory loss (83%), followed by
mechanical hyperalgesia (75%) and thermal hyperalgesia (34%, note that percentages are overlapping and not additive). In
peripheral nerve injury, frequencies were 37%, 59%, and 50%, and in postherpetic neuralgia, frequencies were 31%, 63%, and
46%. For parallel study design, either the estimated effect size of the treatment needs to be high (.0.7) or only phenotypes that are
frequent in the clinical entity under study can realistically be performed. For crossover design, populations under 200 patients
screened are sufficient for all phenotypes and clinical entities with a minimum estimated treatment effect size of 0.5.
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1. Introduction
Neuropathic pain is defined as pain as a result of a lesion or
disease of the somatosensory nervous system18,37 and may
involve diverse etiologies including diabetes, HIV, chemotherapy,
herpes zoster, or nerve injury. Historically, neuropathic pain is
classified based on these etiologies, although similar symptoms
and signs are frequent across these etiologies. Furthermore, it
has become evident in the last decades that an etiology-based
classification approach of patients is not sufficient, as first-line
treatment is often inefficient in more than half of the patients.17 At
the same time, a number of promising new drugs have failed late
trial stages.17,23 Better patient stratification might improve clinical
trial outcome.
Although all neuropathic pain states result from a lesion or
disease of the somatosensory nervous system, the pathogen-
esis and subsequently pathophysiological mechanisms in
damaged and surviving afferent nerve fibers such as conduction
block, ectopic impulse generation, peripheral and central
sensitization may differ between patients. Although these
mechanisms often cannot be tested in patients directly, the
individual patient’s sensory profile, including sensory signs such
as hyperalgesia, allodynia, or hypoesthesia may be linked to
mechanisms.4 A comprehensive way of assessing the sensory
profile of a patient is quantitative sensory testing (QST) in
accordance with the protocol of the German Research Network
on Neuropathic Pain (DFNS).3,33
In a recent study,5 we have shown that QST profiles of
patients with peripheral neuropathic pain reveal 3 distinct
phenotypes, that are (mainly) characterized by (1) thermal and
mechanical sensory loss (SL) (referred to as “sensory loss”
subsequently), (2) preserved sensory function, associated with
mild heat or cold hyperalgesia (labeled “thermal hyperalgesia”
subsequently), and (3) loss of thermal sensation, combined with
mechanical hyperalgesia (MH) or allodynia (referred to as
“mechanical hyperalgesia” subsequently). These phenotypes
can be found across etiologies, but vary in frequency between
these, which has been validated in 2 independent patient
cohorts. To use these phenotypes to stratify patients in clinical
trials or to suggest an efficient treatment for a patient,
a standardized individual allocation of patients must be
available.
The aim of this article is to provide an algorithm based on the
results of our previous work5 and to estimate probabilities for
individual patients to be allocated to each of the 3 named
phenotypes. Based on the patients recruited and published by
the consortia DFNS (German Research Network on Neuro-
pathic Pain),29 IMI (Innovative Medicines Initiative) Europain,10
Neuropain,5 and Pain in Neuropathy Study (PiNS),36 for
neuropathic pain due to diabetic polyneuropathy, peripheral
nerve injury, and after herpes zoster, we provide frequencies of
phenotypes and suggest that minimum sample sizes for
phenotype-stratified trials.
2. Methods
2.1. Consortia
The international consortia DFNS (German Research Network on
Neuropathic Pain29), IMI (Innovative Medicines Initiative) Euro-
pain, Neuropain,5,10 and Pain in Neuropathy Study (PiNS36)
participated in collecting and analyzing these data. All participat-
ing centers underwent strict quality control,28,40 and a recent
analysis of heterogeneity between centers has shown that the
data can be analyzed as a homogenous data set.39
2.2. Quantitative sensory testing protocol
Quantitative sensory testing according to the DFNS protocol
assesses 13 parameters: cold detection threshold and warm
detection threshold (WDT), thermal sensory limen, paradoxical
heat sensations (PHS), cold pain and heat pain thresholds,
mechanical pain threshold and mechanical pain sensitivity (MPS),
dynamical mechanical allodynia (DMA), pressure pain threshold
(PPT), wind-up ratio, tactile (mechanical) detection threshold, and
vibration detection threshold. Thermal sensory and pain thresholds
were measured using either a TSA 2001-II (MEDOC, Israel) or an
MSA (SOMEDIC, Sweden) that increased or decreased temper-
ature by 1˚C per second.33,34 Mechanical detection threshold was
defined as the geometricmean of 5 series of stimuli ascending and
descending between 0.25 and 512 mN by a standardized set of
von Frey hairs, mechanical pain threshold as the geometric mean
of 5 series of stimuli ascending and descending by applying
pinprick stimuli between 8 and 512 mN with a standardized
pinprick set (MRC systems, Heidelburg, Germany).34 Mechanical
pain sensitivity and DMA were assessed by applying a total of 50
stimuli (35 pinprick and 15 light tactile in a balanced protocol) and
asking patients to give a pain rating on a 0 (no pain) to 100 (most
intense pain imaginable) Numerical Rating Scale (NRS) scale.
Mechanical pain sensitivity was calculated as the geometric mean
of the pain ratings of the pinprick stimuli and DMA as the geometric
mean of the pain rating of the tactile stimuli. For the wind-up ratio,
the perceived intensity of a single pinprick stimulus was compared
with that of a series of 10 repetitive pinprick stimuli of the same
physical intensity on a 0 to 100 NRS scale, as an average of 5
series.34 Vibration detection threshold was assessedwith a Rydel–
Seiffer-graded tuning fork (64 Hz, 8/8 scale, mean of 3 testing
series), and PPT was determined over muscle with a pressure
gauge device (FDN200; Wagner Instruments, Greenwich, CT),
exerting forces up to 2000 kPa, as amean of 3 series of ascending
stimulus intensities, each slowly increasing (50 kPa/s).34
2.3. Z-transformation
The initial assessment of 180 healthy subjects from the DFNS
reference database revealed that all parameters except PHS and
DMA could be transformed (partly in log-space) to a standard
normal distribution.28,31,33 This process, called Z-transformation,
normalizes all values to amean5 0 and an SD5 1. Subsequently,
all QST results of patients and healthy subjectswere transformed in
accordance with this normalization. Abnormal values are defined
as values beyond the 95% confidence interval (CI). On a z-scale,
this is represented by z-values,21.96 or.1.96. Paradoxical heat
sensation and DMA usually do not appear in healthy subjects and
therefore cannot be transferred to the same scale. Thus, PHS was
transformed to a binary 0/2-variable showing absence (coded as 0)
or presence (coded as 12) of pathological values. Dynamical
mechanical allodynia was transformed to a 0/2/3-variable repre-
senting noDMA (coded as0), DMAwith average pain ratings below
1 (coded as 12), and DMA with average pain ratings between 1
and 100 (coded as 13). The z-transformation normalizes for age
decade, sex, and tested body region, thus making pain and
detection thresholds comparable between patients with different
age and sex and independently of the affected area, ie, nerves
affected eg, at the face or the feet.
2.4. Sorting algorithm and validation
The most common way to establish a sorting algorithm would be
to calculate the distance of the QST profile of an individual patient
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to each cluster centroid. Thiswould, however, exclude all patients
with one ormoremissing QST values (unless these would be filled
in with imputed values), as the distance to a missing value cannot
be calculated. As single missing values are not uncommon in
patients with neuropathic pain and imputations could bias the
results, we decided to use an approach with more intuitive
handling of missing values. Because QST z-values are approx-
imately normally distributed, our approach was based on
normally distributed probabilities. For each QST z-value of each
parameter i and patient n, a probability can be calculated for
a phenotype to be present based on the density function of the
said phenotype:
Fð1Þ : pin;m ¼
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ps2im
q exp
0
B@2
0
B@

xin2mim
2ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2s2im
q
1
CA
1
CA:
with i5 one of 13 QST parameters, n5 the nth patient in a set
of patients,m5 one of 3 phenotypes and conclusively, sim being
the SD of the ith QST parameter for the mth phenotype in the
defining data set,5 mim being the mean z-value of the same QST
parameter and phenotype in the defining data set,5 and finally xin
being the z-value found in the nth patient for the ith QST
parameter.
Although this function will always reach its maximum at
xin5mim, in relation to broadness of the SD, density functions
can become broader or narrower. This affects the maximum
value the density function can reach. To control for these more or
less broad functions, we normalized the formula so that a value
that is equal to the mean of the phenotype equals 100%, leading
to
which can be simplified to
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The resulting probability value ranges from 0% to 100% and
can be calculated for all i 5 13 QST parameters and m 5 3
phenotypes. By averaging the probability over the 13 QST
parameters, we quantify the similarity of the individual
patient’s QST profile to the mean profile of each of the 3
phenotypes.
As a simple way of categorizing patients into phenotypes, we
suggest to sort each patient to the phenotype with the highest
probability value:
(1) Calculate F(3) for each of the 13 QST parameters. Usem and s
from Table 1 for SL.
(2) Average the 13 probabilities (leave out missing value from
average). The resulting value is the probability for this patient to
show the SL phenotype.
(3) Repeat steps 1 and 2, using m and s from Table 1 for thermal
hyperalgesia (TH) and MH.
(4) Allocate the patient to the phenotype with the highest
probability value.
The algorithm as described above was applied to the n5 902
patients from the original cohort5 to demonstrate its general
sorting capacity to reproduce the original cluster allocations.
2.5. Simplified phenotyping
As the DFNS protocol is comprehensive, it might be too complex
to be applied in all clinical settings and in large clinical trials. In our
previous analysis, we showed that 2 parameters (WDT and MPS)
explain large parts of the variance between the phenotypes.
Therefore, we also calculated the accuracy of a phenotyping
based on WDT and MPS in comparison to a phenotyping using
the full protocol.
2.6. Discrimination analysis against healthy subjects
To show if and how the algorithm can discriminate patients with
neuropathic pain from healthy subjects, we introduced a forth
probability—not for a phenotype, but for being healthy. For this
purpose, we applied the definition of QST z-values, to which
a group of healthy subjects ideally has a z-valuemean5 0 (m) with
a SD5 1 (s) for each QST parameter. The original cluster patient
cohort5 (n 5 902) and n 5 188 healthy subjects21 from the
European cohort39 underwent a modified version of the
algorithm:
(1) Calculate F(3) for each of the 13 QST parameters. Usem and s
from Table 1 for healthy subjects.
(2) Average the 13 probabilities. The resulting value is the
probability for this patient to show a healthy profile.
(3) Repeat steps 1 and 2, using m and s from Table 1 for SL, TH,
and MH.
As this version of the algorithm does not sort each subject
simply to the phenotype with the highest probability, this leaves
every subject with 4 probabilities, one for each of the 3
phenotypes, and one for being healthy.
The probability of being healthy was used for a receiver
operating characteristics (ROC) plot.46 This graphical tool for
assessing discriminatory power plots the false-positive rate (1 2
specificity) on the x-axis vs the sensitivity of detecting patients on
the y-axis for all possible probability values of being healthy. Each
step in the ROC plot represents the specificity and sensitivity of
one certain percentage. To assess the overall quality of
separating healthy subjects and patients via the probability for
being healthy, the area under curve and its 95% CI were
calculated.8 To define a minimum probability, at which a subject
should be considered being healthy, the probability with the
highest Youden Index (sensitivity minus false-positive rate45) was
chosen.
2.7. Deterministic and probabilistic algorithm
To this point, we use a deterministic approach, ie, each patient is
allocated to exactly one phenotype. It is, however, our belief that
a patient may be allocated to more than 1 phenotype, so with the
Fð2Þ : ppin;m ¼
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ps2im
q exp
0
B@2
0
B@

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q
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cut-off determined for healthy subjects above transferred onto
patients, we can suggest 2 alternative versions of the algorithm,
a deterministic one:
(1) Calculate F(3) for each of the 13 QST parameters. Usem and s
from Table 1 for healthy subjects.
(2) Average the 13 probabilities. The resulting value is the
probability for this patient to show a healthy profile.
(3) Repeat steps 1 and 2, using m and s from Table 1 for SL, TH,
and MH.
(4) Allocate the patient to the phenotype with the highest
probability value.
And a probabilistic version, where steps 1 to 3 remain identical
and step 4 is exchanged with
(4) Sort the patient to all phenotypes with a probability above the
value with the highest Youden Index found in the discrimination
between patients and healthy subjects. If the only probability
over this cut-off is for being healthy or no phenotype reaches
a probability above this cut-off, the patient should be excluded.
These 2 versions were used for all analyses below and are
presented alongside. The simplified version of the algorithm is the
same, except in step 1, only WDT andMPS are used instead of all
13 QST parameters, as these parameters have shown to explain
the largest part of variability between the 3 phenotypes in our
previous analysis.5
2.8. Frequency of phenotypes across clinical entities
If a new drug would be tested for efficacy in a phenotype-stratified
subgroupwith neuropathic pain of any single etiology, thiswould only
be meaningful if the said phenotype appears in a relevant frequency
within this etiology. To show how frequent these phenotypes are
across 3 common etiologies of neuropathic pain, we applied the
algorithm to patients suffering from neuropathic pain due to diabetic
polyneuropathy, peripheral nerve injury, or postherpetic neuralgia
from the databases of our previous studies.5,9,10,29,36
2.9. Sample size recommendations
On the basis of the frequencies found in the clinical entities, we
calculated the size of a group of patients who need to be
screened with either full or simplified phenotyping to find
a subpopulation large enough to perform a trial that still reaches
a power of 80% for an effect size of 0.3, 0.5, and 0.7 at an alpha
level of 0.05, for a crossover and parallel design. The sample sizes
presented in this article are examples, and we encourage all
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Table 2
Cross-tabulation of dominant phenotype identified using
cluster analysis vs the proposed new, individualized algorithm
(rows) for full and simplified phenotyping (in brackets).
Individual Cluster
Sensory loss
(n 5 381)
Thermal
hyperalgesia
(n 5 302)
Mechanical
hyperalgesia
(n 5 219)
Sensory loss, n 5 356
(356)
325 (301) 15 (29) 16 (26)
Thermal hyperalgesia,
n 5 267 (282)
3 (34) 235 (219) 29 (29)
Mechanical hyperalgesia,
n 5 279 (264)
53 (46) 52 (54) 174 (164)
Overall, both classifications revealed a strong concordance of solutions (81% of the cases, 76% for simplified
phenotyping using only warm detection threshold and mechanical pain sensitivity).
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readers to tailor them to their individual needs. We recommend
the usage of free software G*Power,15 but many other statistical
packages provide similar tools. The following information is
required before starting: alpha level (usually 0.05), power (usually
0.8, 0.9, or 0.95), test family (usually t test for independent
(parallel design) or dependent (crossover design) mean, or chi-
squared for dichotomous outcome), and the estimated effect size
in the phenotype of interest. Effect sizes are related to a mean
treatment effect andSDbetween treatment response, eg, amean
effect of 2 on a 0 to 10 NRS scale with an SD of 4 corresponds to
an effect size of 0.5, a mean effect of 3.5 with an SD of 5
corresponds to an effect size of 0.7, and amean effect of 1with an
SD of 3 corresponds to an effect size of 0.3, and many other
combinations are possible. With this information, the size of the
subgroup of patients with the phenotype of interest that needs to
be included can be calculated. To determine the size of the overall
population which needs to be screened to find a subgroup of the
calculated size, divide the subgroup size by the frequency of the
phenotype in the etiology of interest as presented in the results
section, in regard to the algorithm used (deterministic or
probabilistic) and the phenotyping protocol (full or simplified).
3. Results
3.1. Sorting algorithm
Individual allocation replicates the original cluster analysis5 in 81%
of the cases for the complete QST protocol using 13 parameters
and in 76% of the cases using simplified phenotyping. Cohen
kappa coefficient of agreement (scale: 05 random classification, 1
5 perfect agreement between methods) was 0.72 (95% CI: 0.57-
0.87) for the complete protocol and 0.63 (95% CI: 0.48-0.78) for
simplified phenotyping, both valuesmay be categorized as “good,”
although no universal guideline for interpreting Cohen kappa
exists.19 Most common shifts were former SL or TH to MH (14 and
17%, respectively), and least common shift was former SL to TH
(,1%). Patient shift between phenotypes is shown in Table 2.
3.2. Discrimination analysis against healthy subjects
The ROC-area under curve value (scale: 0.5-1, 0.5: no
discriminatory power, 1: perfect discrimination) for separating
Figure 1. Receiver Operating Characteristic analysis of the discriminatory
power of the proposed algorithm to separate between patients with
neuropathic pain and healthy subjects. Black line: full sensory testing, gray
line: reduced protocol, using only warm detection threshold and mechanical
pain sensitivity. The green dotted diagonal line indicates random classification
(“coin flipping”). The area marked by dashed lines indicates the optimum ratio
of sensitivity and specificity at 64% for probability for being healthy for full
phenotyping (reduced phenotyping: 63%).
Figure 2. Sensory phenotype probabilities and probability of being healthy for (A) n5 902 patients with neuropathic pain and (B) n5 188 healthy subjects. Gray
line: probability for being healthy, blue line: sensory loss, red line: thermal hyperalgesia, yellow line: mechanical hyperalgesia. Subjects on the x-axis are sorted by
their individual probability of being healthy. Dotted line: a phenotype with a probability over 64% should be considered relevant in the individual patient. Thirteen
healthy subjects (7%) did not reach this criterion, 198 patients (22%) had profiles consistent with being normal.
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patients with neuropathic pain and healthy subjects using the
probability for being healthy was found to be 0.915 (95% CI:
0.898-0.932), indicating high discriminatory power (Fig. 1). For
simplified phenotyping, discriminatory power was significantly
lower (0.785, 0.753-0.815). The Youden Index was found to be
the highest at a probability of 64%—ie, each subject with
a probability value below 64% should be considered as a patient,
and when above 64% as being healthy. Although this classifica-
tion is valid in 94% of healthy subjects, sensitivity in detecting
patients is 78% (ie, 22% of patients with neuropathic pain have
a sensory profile with a probability for being healthy above 64%).
Individual probabilities for each phenotype for patients and
healthy subjects are plotted in Figure 2. For simplified phenotyp-
ing, the highest Youden Index was found at a very similar value of
63% with similar sensitivity (74%) but very reduced specificity
(72%). Because of the high similarity of cut-offs, 64% was used
for both full protocol and simplified phenotyping.
3.3. Frequency of phenotypes across clinical entities
From the databases of the DFNS, IMI Europain, Neuropain, and
the Pain in Neuropathy Study (PiNS), a total of 151 patients with
painful diabetic polyneuropathy, 335 patients with painful
peripheral nerve injury, and 97 patients with postherpetic
neuralgia who had been part of previous analyses5,9,10,29,36
underwent both deterministic and probabilistic phenotyping
(see Table 3 for patients’ basic characteristics). Frequencies of
phenotypes are presented in Table 4, and frequency and
overlap between phenotypes for the full protocol and for each
clinical entity are displayed in Venn and bar diagrams in
Figure 3.
3.4. Overlap in the probabilistic algorithm
Of the diabetic polyneuropathy cohort, 4 patients (3%) were
neither sorted to any phenotype nor healthy and had to be
excluded. Twenty-seven patients (18%) were consistent with all 3
phenotypes and 86 (57%) with 2 phenotypes. In peripheral nerve
injury, 70 (21%) patients were not assigned to any phenotype and
2 (,1%) only to the healthy profile; these patients were all
excluded. Sixty-three (19%) patients were assigned to the healthy
profile and at least 1 additional phenotype. Seventeen patients
(5%) were allocated to all 3 phenotypes, 120 (36%) to 2
phenotypes. In postherpetic neuralgia, 29 (30%) patients were
not possible to be assigned to any phenotype; these patients
were excluded. Six patients (6%) were consistent with all 3
phenotypes, 27 (28%) with 2 phenotypes.
3.5. Accuracy of simplified phenotyping
Overall, 57% of patients with diabetic polyneuropathy, 62% of
patients with peripheral nerve injury, and 58% of patients with
postherpetic neuralgia were sorted into the same phenotype
allocated when the full protocol was applied. The sensitivity of the
simplified algorithm, however, is dependent on a combination of
phenotype of interest and the clinical entity under study: In
diabetic polyneuropathy, 74% of SL patients were correctly
identified, but only 48% of patients with TH and 43% of patients
with MH. In patients with peripheral nerve injury, allocation
accuracy was more balanced between phenotypes (75% for SL,
60% for TH, and 64% for MH). In patients with postherpetic
neuralgia, sensitivity was very low for SL (24%), and better for
thermal (76%) andMH (56%). Consequently, low sensitivity of the
simplified algorithm is linked to low frequency of certain
Table 3
Patient characteristics separately for diabetic polyneuropathy, peripheral nerve injury, and postherpetic neuralgia.
n (subjects) Age (mean 6 SD) Female Disease duration <1 y Disease duration >5 y
Painful diabetic polyneuropathy 151 64 6 12 62 (41) 3 (2) 112 (74)
Peripheral nerve injury 335 49 6 13 158 (57) 70 (21) 49 (15)
Postherpetic neuralgia 97 70 6 10 57 (59) 38 (39) 11 (11)
Sex and disease duration presented as n (%). All patients have been part of previous publications.
Table 4
Frequency of each phenotype in diabetic polyneuropathy, peripheral nerve injury, and postherpetic neuralgia, separately for the
deterministic and probabilistic algorithm, and for full and simplified phenotyping.
Phenotyping protocol Full protocol Simplified phenotyping
Algorithm Deterministic, % Probabilistic, % Deterministic, % Probabilistic, %
Diabetic polyneuropathy
Healthy profile 4 14 4 12
Sensory loss 64 82 61 64
Thermal hyperalgesia 13 33 9 20
Mechanical hyperalgesia 19 75 26 36
Peripheral nerve injury
Healthy profile 8 19 14 22
Sensory loss 24 29 26 22
Thermal hyperalgesia 31 44 24 33
Mechanical hyperalgesia 37 52 36 36
Postherpetic neuralgia
Healthy profile 6 19 9 20
Sensory loss 20 22 23 12
Thermal hyperalgesia 30 39 28 35
Mechanical hyperalgesia 44 49 40 34
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phenotypes (especially TH in diabetic polyneuropathy and SL in
postherpetic neuralgia), affecting the sample size recommendations
(Table 5).
4. Discussion
In a commentary to our findings of 3 distinct sensory phenotypes
in patients suffering from neuropathic pain, we were asked to
develop an algorithm to allocate individual patients to said
phenotypes.11 This work can be considered as a response to this
request. We have developed an algorithm that enables individual
allocation of patients to one or more sensory phenotypes, and,
further, can separate patients from healthy subjects with a very
high specificity of 94% and a sensitivity of 78%. All phenotypes
are present in diabetic polyneuropathy, peripheral nerve injury,
and postherpetic neuralgia in reasonable frequencies, resulting in
acceptable estimated sample sizes for phenotype-stratified trials,
especially if crossover-designed studies are planned. The
algorithm will be implemented in the next update of QST
managing software eQUISTA (distributed by StatConsult,
Magdeburg, Germany), but the algorithm itself is free to use.
4.1. Phenotype stratification by sensory profiles
A mechanistic classification of neuropathic pain has been under
debate for over 25 years.4,6,12,16,41 Although a series of studies
showed that a post hoc responder analysis can reveal
phenotypes that are important to predict treatment re-
sponse,1,2,24,30,32,35,42,43 the first phenotype-stratified, random-
ized, placebo-controlled trials have been published only
recently.9,10 In these studies, oxcarbazepine showed a superior
effect over placebo in a subgroup with “irritable nociceptors,”
a group with a sensory profile very similar to the TH phenotype in
this study. By contrast, for topical lidocaine no group difference
could be demonstrated.
The main problem with the definition of “irritable nociceptors”
based on abnormal QST values (ie, only values outside the 95%
CI for healthy subjects are considered) and loss and gain of
functions patterns29,33 is that it is based on a statistically sound,
but conservative approach with (comparably) low sensitivity. For
instance in diabetic polyneuropathy, the “irritable nociceptor”
phenotype is virtually absent.36
By contrast, the approach taken in this study does not rely on
abnormal QST values outside the 95% CI, but focuses on
similarity of the entire sensory profile to cluster centroids instead.
An appealing advantage of this dynamic method can be seen in
Figure 3A. The TH phenotype, which is similar to the “irritable
nociceptor” and may have similar underlying mechanisms of pain
generation, is found to be a prominent phenotype in a reasonable
subgroup of roughly one-third of the patients with neuropathic
pain due to diabetic polyneuropathy.
4.2. Effort of stratifying populations
To use stratification into subgroups in clinical trials, a large patient
population must be screened beforehand with QST to yield
a smaller final stratified study population. Thus, a solid sample
size calculation of the number of patients necessary to screen is
a prerequisite for a stratified study. In Table 5, we present sample
size numbers for screening of populations for painful diabetic
polyneuropathy, painful peripheral nerve injury and postherpetic
neuralgia in relation to estimated effect size (0.3 vs 0.5 vs 0.7) and
study design (parallel vs crossover). Crossover sample sizes are
overall “realistic” numbers–across phenotypes and clinical
etiology based-entities, and are recommended for phase 2 trials.
If a parallel study design is intended for phase 3 trials, however,
phenotype stratification may only be possible if a high effect size
(eg, 0.7) is anticipated.
4.3. Similarity to experimentally studied mechanisms and
stratification recommendations
As discussed en detail,5 the phenotypes described in this study
resemble sensory phenotypes that can be experimentally in-
duced in healthy subjects. The SL phenotype is similar to
previously described “deafferentation” or “painful hypoesthesia”
subgroups6,16,38 and shows elements that can be induced by
a compression nerve block.20,44 Edwards et al.13 have shown
that patients with higher heat pain threshold–like these patients
present–show an improved response to opioid treatment. So,
Figure 3. Sensory phenotype frequency and overlap between phenotypes for
(A) diabetic polyneuropathy, (B) peripheral nerve injury, and (C) postherpetic
neuralgia. Gray: healthy (H), blue: sensory loss (SL), red: thermal hyperalgesia
(TH), yellow: mechanical hyperalgesia (MH). First bar (DET): deterministic
algorithm (adds to 100%), 3 subsequent bars: probabilistic approach (a patient
may be allocated to more than one phenotype, percentages are not additive).
Bars are to scale, sizes of the circles in Venn diagrams and their overlaps are
illustrative, not to scale.
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a study of a centrally acting drug, eg, antidepressant or opioid,
could be suggested to be stratified for this subgroup.5,7
The sensory profile of the TH phenotype resembles UVB burn
lesion22 and the previously described “irritable nociceptor”.10,16
We suggest that sodium channel blockers would be most
effective for patients with this phenotype,5 supported by the
findings of Demant et al.10
The MH phenotype shows similarities to the profile induced by
high-frequency electrical stimulation of the skin26 and the
previously described “neurogenic hyperalgesia” and “central
sensitization”.6,16 A trial investigating a calcium channel a2d
subunit inhibitor (coll.: gabapentinoid) or N-methyl-D-aspartate
antagonist might target this phenotype,5 as indicated by a post
hoc analysis of patients suffering from HIV-related painful
neuropathy treated with pregabalin.35
4.4. Limitations
It should be emphasized that the comparison to experimentally
induced mechanisms above is anecdotal rather than compre-
hensive.25,27 Finding commonalities between these clinical QST
profiles and the QST profiles induced by the various surrogate
models for neuropathic pain will be an important upcoming task
of its own.
The sample size calculations in Table 5 show both advantage
and disadvantage of a QST-based phenotype stratification for
clinical trials. A novel drug that is aiming at a phenotype that is only
present in a fifth of the population will never show an effect
superior to placebo in a nonstratified population. However, many
patients must be screened to identify an eligible subpopulation,
and screening with QST needs substantial training to be reliable
and should be done by certified centers. Furthermore, some QST
parameters are mechanistically linked and therefore probably
intercorrelated (eg, CDT or WDT and thermal sensory limen). In
the presented algorithm, these domains may be slightly over-
weighted. Although beyond the scope of this article, a factorial
analysis of the QST protocol is one of the upcoming tasks to show
the importance and meaning of each parameter in relation to the
full protocol. In the long run, both for large trials and daily clinical
practice, an approximation via a simple bed-side testing protocol
would be highly valuable.
Although the presented algorithm offers a criterion for
excluding healthy subjects, this should be considered within the
clinical context. We decided on a rather conservative criterion
with high specificity. It has to be noted that patients eligible for
clinical trials are usually screened beforehand, have been shown
to have a lesion or disease, and have spontaneous pain—a
sensory profile that resembles healthy subjects does not
necessarily exclude a patient from a trial. Confirming neuropathic
pain relies on a history of a relevant neurological lesion or disease,
anatomically plausible pain distribution and sensory signs, and
finally on diagnostic tests confirming the lesion or disease.18 Our
algorithm assesses sensory signs, but only on an averaged level:
eg, a strongly decreased vibration or thermal detection in an
otherwise normal profile would be considered a negative sensory
sign, but might still result in a high averaged probability of being
healthy in this algorithm.
We present 2 methods of sorting patients to phenotypes, but
we do not recommend one or the other in general, because we
think both have advantages and disadvantages. The determin-
istic approach, sorting each patient to exactly one phenotype,
ignores that multiple pathomechanisms may be present in
a patient, and that these mechanisms may overlay each other
and result in a sensory phenotype that cannot easily be allocated
to one phenotype over the other. The probabilistic approach,
however, holds its own challenges: Although the overlap between
phenotypes is reasonable for peripheral nerve injury and
postherpetic neuralgia, patients with diabetic polyneuropathy
Table 5
Number of patients who need to be screened to find a subpopulation with a given phenotype large enough to conduct a study
with a power of 80% with an alpha-level of 0.05 and a given effect size.
Study design Parallel Crossover
Effect size 0.3 0.5 0.7 0.3 0.5 0.7
Diabetic polyneuropathy
Sensory loss 550 (577) 200 (210) 106 (111) 141 (148) 53 (56) 30 (31)
429 (550) 156 (200) 83 (106) 110 (141) 41 (53) 23 (30)
Thermal hyperalgesia 2708 (3911) 985 (1422) 523 (756) 692 (1000) 262 (378) 146 (211)
1067 (1760) 388 (640) 206 (340) 273 (450) 103 (170) 58 (95)
Mechanical hyperalgesia 1853 (1354) 674 (492) 358 (262) 474 (346) 179 (131) 100 (73)
469 (978) 171 (356) 91 (189) 120 (250) 45 (94) 25 (53)
Peripheral nerve injury
Sensory loss 1467 (1354) 533 (492) 283 (262) 375 (346) 142 (131) 79 (73)
1214 (1600) 441 (582) 234 (309) 310 (409) 117 (155) 66 (86)
Thermal hyperalgesia 1135 (1467) 413 (533) 219 (283) 290 (375) 110 (142) 61 (79)
800 (1067) 291 (388) 155 (206) 205 (273) 77 (103) 43 (58)
Mechanical hyperalgesia 951 (978) 346 (356) 184 (189) 243 (250) 92 (94) 51 (53)
677 (978) 246 (356) 131 (189) 173 (250) 65 (94) 37 (53)
Postherpetic neuralgia
Sensory loss 1760 (1530) 640 (557) 340 (296) 450 (391) 170 (148) 95 (83)
1600 (2933) 582 (1067) 309 (567) 409 (750) 155 (283) 86 (158)
Thermal hyperalgesia 1173 (1257) 427 (457) 227 (243) 300 (321) 113 (121) 63 (68)
903 (1006) 328 (366) 174 (194) 231 (257) 87 (97) 49 (54)
Mechanical hyperalgesia 800 (880) 291 (320) 155 (170) 205 (225) 77 (85) 43 (48)
718 (1035) 261 (376) 139 (200) 184 (265) 69 (100) 39 (56)
First row: deterministic algorithm (each patient is sorted to exactly phenotype), second row: probabilistic algorithm (each patient may be allocated to no, one, or more than one phenotype). Values in brackets show the number
needed to be screened with the simplified protocol. Numbers in bold indicate that 200 or less patients need to be screened. Effect sizes are related to mean treatment effect and SD between treatment response, eg, mean effect
on Numerical Rating Scale 0 to 10 scale: 3.5, SD: 5 5 effect size 0.7; mean effect: 2, SD: 4 5 effect size 0.5; mean effect: 1, SD: 3 5 effect size 0.3.
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tend to present more than 1 phenotype with substantial
probability. This effect, probably caused by the overwhelming
frequency of loss symptoms in these patients, may dilute
especially the MH phenotype. When screening for these
phenotypes in patients with diabetic polyneuropathy, this
limitation should be considered by rather using the deterministic
algorithm. For peripheral nerve injury and post herpetic neuralgia,
a notable part of the patients (21% and 30%, respectively) is not
sorted to any phenotype in the probabilistic algorithm and
therefore excluded from the analysis. Although this is acceptable
for phenotype-stratified trials, it becomes a problem if the
algorithm would be used for designing individual patients’
treatment strategy in the future. Again, the deterministic
approach might be favorable in this case.
Although this analysis focuses on trial design, it is our belief that
this or a similar approach will become important in guiding
individual patients’ treatment in the future. This topic is heavily
under debate (and there is dissent evenwithin the author group of
this article). Although we agree that at the moment we cannot
present a solution to design individualized treatment based on
sensory phenotypes, this analysis along with others may pave the
way towards individualized pain treatment of patients with
specific sensory phenotypes with future medicines.5,7,10,30,41
5. Conclusions
In summary, we present an algorithm that can be used for
stratification of patients suffering from peripheral neuropathic
pain in clinical trials and may in the future indicate individual
patients’ optimal treatment strategies. Although all 3 phenotypes
are present in diabetic polyneuropathy, peripheral nerve injury,
and postherpetic neuralgia, frequencies differ, which should
affect the number of patients screened for clinical trials. As a result
of our previous analysis,5 the European Medicines Agency’s
(EMA) committee for medicinal products for human use
recommends the phenotype stratification presented here for
determining eligible sensory phenotypes of patients in exploratory
trials on neuropathic pain, as also incorporated in the new EMA
guideline for clinical development of new treatments for pain.14
We encourage validation of this concept by applying it in
prospectively phenotype-stratified trials on peripheral neuro-
pathic pain.
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